Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

How accurate are stock forecasts?

Stock forecasts are based on technical and fundamental analysis but should not be considered as guaranteed predictions. Past performance does not guarantee future results.

How do I analyze GLUE stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate GLUE investment potential.

What is GLUE stock price today?

Get real-time GLUE stock price, historical data, and price charts on Financhill. Track GLUE performance with our advanced analysis tools.

Is GLUE a good investment?

Evaluate GLUE investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy GLUE stock?

To buy GLUE stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of GLUE?

View detailed market capitalization data and company valuation metrics for GLUE on our comprehensive analysis page.

What is the P/E ratio of GLUE?

Use our fundamental analysis tools to view GLUE P/E ratio and compare valuation metrics with industry peers.

What are GLUE earnings?

View GLUE earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

Monte Rosa Therapeutics, Inc. Stock Predictions

AI Powerhouse Raises Price - But Room Remains

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering and involves risk, including the possible loss of principal. Please read the offering circular and related risks at invest.radi

Buy

GLUE
Monte Rosa Therapeutics, Inc.

Last Price:

$17.24

Seasonality Move:

6.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Missed $0.81? RAD Intel Now Open at $0.85/Share

Monte Rosa Therapeutics, Inc. Stock Forecast

Over the next 52 weeks, Monte Rosa Therapeutics, Inc. has on average historically risen by 37.5% based on the past 4 years of stock performance.
Monte Rosa Therapeutics, Inc. has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
Is Monte Rosa Therapeutics, Inc. Stock Undervalued?

The current Monte Rosa Therapeutics, Inc. [GLUE] share price is $16.86. The Score for GLUE is 69, which is 38% above its historic median score of 50, and infers lower risk than normal.
GLUE is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will Monte Rosa Therapeutics, Inc. Stock Go Up Next Year?

Over the next 52 weeks, Monte Rosa Therapeutics, Inc. has on average historically risen by 37.5% based on the past 4 years of stock performance.

Monte Rosa Therapeutics, Inc. Stock Rating

Buy

Monte Rosa Therapeutics, Inc. (GLUE) is a Buy

Is Monte Rosa Therapeutics, Inc. overpriced?

Monte Rosa Therapeutics, Inc. has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

Monte Rosa Therapeutics, Inc. Stock Price History

Is GLUE stock going to rise?

Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and GLUE is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:

NASDAQ

Country:

United States

Industry:

Biotechnology

Sector:

Health Care

Type:

stock

Website:

monterosatx.com

52-Week Data

52-Week High:

16.99

52-Week Low:

3.50

Prediction Charts

Market Cap:

1.1B

Price in USD:

16.86

Volume:

1.3M

Beta:

1.63

Technical Analysis

SMA50:

11.59

SMA100:

8.38

SMA200:

6.67

52-Wk Change:

70.99%

Stock Predictions

Is Monte Rosa Therapeutics, Inc. stock public?

Yes, Monte Rosa Therapeutics, Inc. is a publicly traded company.
What is the Monte Rosa Therapeutics, Inc. stock quote today?

The Monte Rosa Therapeutics, Inc. stock price is 16.86 USD today.
How to buy Monte Rosa Therapeutics, Inc. stock online?

You can buy Monte Rosa Therapeutics, Inc. shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date	Opening	Closing	Minimum	Maximum
Nov-13	13.99	14.32	14.35	13.73
Nov-14	14.07	14.36	14.62	13.93
Nov-17	14.40	13.61	14.49	13.53
Nov-18	13.48	13.78	13.82	12.94
Nov-19	13.76	14.14	14.45	13.74
Nov-20	14.44	13.52	14.58	13.48
Nov-21	13.45	14.22	14.38	13.27
Nov-24	14.21	15.76	16.66	14.19
Nov-25	15.72	16.02	16.35	15.47
Nov-26	16.06	15.99	16.30	15.86
Nov-28	16.10	16.17	16.24	15.68
Dec-1	16.03	15.78	16.17	15.68
Dec-2	15.83	15.41	16.02	15.35
Dec-3	15.54	16.86	16.99	15.21

Monte Rosa Therapeutics, Inc. Earnings

Monte Rosa Therapeutics, Inc. Earnings Report: Per Share Monte Rosa Therapeutics, Inc. Earnings Q1 Q2 Q3 and Q4 last year and next year.

Monte Rosa Therapeutics, Inc. Forecast Revenue Growth

Monte Rosa Therapeutics, Inc. Stock Analysis: Historical quarterly revenues per share for Monte Rosa Therapeutics, Inc. and historical quarterly revenue growth:

Analysts estimate an earnings increase this quarter of $0.11 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.02 per share, and a decrease next year of $1.17 per share.

* Monte Rosa Therapeutics, Inc. stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.